SynthesisMetabolic brain disease2017
Correlation of rs9331888 polymorphism with Alzheimer's disease among Caucasian and Chinese populations: a meta-analysis and systematic review.
Synthesis in Metabolic brain disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Correlation of PICALM polymorphism rs3851179 with Alzheimer's disease among Caucasian and Chinese populations: a meta-analysis and systematic review.Metabolic brain disease · 2018Pooled it
- Comprehensive Overview of Alzheimer's Disease: Etiological Insights and Degradation Strategies.International journal of molecular sciences · 2024Review
- Article
- Lipoprotein Metabolism, Protein Aggregation, and Alzheimer's Disease: A Literature Review.International journal of molecular sciences · 2023Review
- Clusterin in Alzheimer's Disease: Mechanisms, Genetics, and Lessons From Other Pathologies.Frontiers in neuroscience · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clusterin polymorphism (rs9331888) was reported to be associated with the susceptibility to alzheimer's disease (AD). Nevertheless, the results were inconclusive. To derive a more precise estimation of this association, this meta-analysis was conducted. We've conducted a comprehensive search of PubMed, Embase, CNKI and AlzGene database for case-control studies published throughout October, 2016 that evaluated the role of rs9331888 gene variants in AD patients. Odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated to assess the strength of associations between the rs9331888/C > G polymorphism and AD disease. A total of 9 studies were enrolled in the Meta Analysis. The overall analysis revealed a significant association between the rs9331888/C > G polymorphism and AD disease in the recessive model (GG vs. GC + CC: OR = 1.11, 95% CI: 1.05-1.18; P < 0.01). Sub-group analysis revealed that the Caucasian populations which with recessive model (GG vs. GC + CC: OR = 1.12, 95% CI: 1.06-1.2; P < 0.01) were dramatically related to AD, while no significant association was found in the Chinese populations among the five genetic models. Our meta-analysis demonstrated that the rs9331888/C > G polymorphism in the clusterin gene might contribute to AD susceptibility especially in Caucasian populations. Whereas the relationship of the polymorphism to the disease in Chinese populations was still in controversial. Additional well-designed studies, with larger sample sizes, are required to further elucidate this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.